Posted April 26, 2019
Earlier this year, the U.S. Food and Drug Administration (FDA) gave the green light to fast-track approval status for ImmusantT’s experimental vaccine Nexvax2, designed to protect patients with HLA-DQ2.5-dependent celiac disease from the effects of gluten exposure. Read more.